Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. reports pharmaceutical developments across immunology, neuroscience, oncology and Allergan Aesthetics. Recurring updates include financial results by product portfolio, clinical and real-world data for therapies such as SKYRIZI and RINVOQ, FDA regulatory submissions and response letters, and medical-conference presentations in inflammatory bowel disease and other immune-mediated conditions.
Company news also covers pipeline spending, acquired in-process research and development, manufacturing capacity for medicines in core therapeutic areas, and investor conference appearances. AbbVie’s product references commonly include SKYRIZI, RINVOQ, Botox Therapeutic, Vraylar, Ubrelvy, Qulipta, Venclexta, Imbruvica and Elahere.
AbbVie and Plexium have announced a strategic partnership to develop Targeted Protein Degradation (TPD) therapeutics aimed at neurological conditions. This collaboration leverages AbbVie's neuroscience expertise and Plexium's innovative TPD technology platform. Plexium will handle preclinical research, receiving upfront payments and potential royalties upon commercialization. AbbVie will oversee global development and commercialization of the outcomes from this partnership. This venture is designed to tackle complex neurological diseases, expanding the capabilities of both companies in this challenging therapeutic area.
Dragonfly Therapeutics and AbbVie are expanding their collaboration to develop new drug candidates targeting autoimmune and fibrotic diseases using Dragonfly's TriNKET™ platform. AbbVie licensed its first TriNKET™ candidate in January 2021 as part of a multi-target collaboration that began in November 2019. Under the new agreement, AbbVie will pay an upfront fee, plus future milestone payments and royalties to Dragonfly for exclusive worldwide rights to multiple new candidates. Both companies aim to deliver innovative treatments to patients.
On April 19, 2022, Allergan, an AbbVie company (NYSE: ABBV), announced new data to be presented at the upcoming ASCRS Annual Meeting in Washington, D.C., from April 22-26, 2022. Key highlights include updates on VUITYTM, the first FDA-approved eye drop for presbyopia, and the XEN® Gel Stent for glaucoma management. Presentations will showcase data on VUITY's safety, efficacy, and usage in various populations, as well as analyses regarding the XEN® Gel Stent's effectiveness for refractory glaucoma. The commitment to innovation in eye care is emphasized by Michael R. Robinson, M.D.
AbbVie (NYSE: ABBV) will release its first-quarter 2022 financial results on April 29, 2022, before the market opens. A live webcast of the earnings conference call will take place at 8 a.m. CT, accessible via AbbVie's Investor Relations website. An archived edition will be available later that day. AbbVie aims to address serious health issues through innovative medicines across various therapeutic areas, including immunology, oncology, and virology. For more details, visit abbvie.com.
AbbVie and Genmab announced topline results from the EPCORE™ NHL-1 clinical trial for epcoritamab (DuoBody®-CD3xCD20), targeting relapsed/refractory large B-cell lymphoma (LBCL). The trial involved 157 patients with a confirmed overall response rate (ORR) of 63.1% and a median duration of response (DOR) of 12 months. Common adverse events included cytokine release syndrome (49.7%) and neutropenia (21.7%). The companies plan to engage global regulatory authorities and present data at a future medical conference.
Genmab (NASDAQ: GMAB) and AbbVie (NYSE: ABBV) announced positive topline results from the EPCORE™ NHL-1 clinical trial for epcoritamab, a bispecific antibody targeting large B-cell lymphoma (LBCL). The trial, involving 157 patients, demonstrated an overall response rate (ORR) of 63.1%, surpassing efficacy benchmarks, with a median duration of response (DOR) of 12 months. The companies will engage global regulatory authorities to determine next steps and plan to present detailed data at an upcoming medical meeting.
Summary not available.
AbbVie has announced promising results from a Phase 2 trial of navitoclax combined with ruxolitinib for myelofibrosis, a challenging blood cancer. The exploratory analysis included 34 patients, with a 100% survival estimate for those showing grade improvement in bone marrow fibrosis after over two years. Importantly, 38% of patients had a significant improvement in fibrosis, while 23% showed a reduction in variant allele frequency. Presented at AACR 2022, these findings support ongoing Phase 3 studies and suggest navitoclax may enhance patient outcomes in myelofibrosis.
AbbVie announced positive results from the Phase 3 VIRGO trial, evaluating the investigational twice-daily administration of VUITY, an eye drop for presbyopia. The study demonstrated significant improvement in near vision without compromising distance vision. A total of 230 participants were involved, with results indicating that participants gained three lines or more in near visual acuity at Day 14. These findings will support a supplemental New Drug Application to the FDA in Q2 2022. While VUITY is FDA-approved for once-daily use, twice-daily administration is not yet approved.
Allergan Aesthetics, part of AbbVie (NYSE: ABBV), has entered a groundbreaking partnership with Resorts World Las Vegas to become the preferred aesthetics and rewards partner at the resort. This multiyear agreement grants Allergan exclusive branding rights to the Allē Lounge on 66 and the Allē Backstage space at the Resorts World Theatre. The partnership aims to enhance consumer engagement and introduce millions of visitors to Allergan’s product portfolio. This marks Allergan's first branding of a dedicated area at a major resort.